Skip to main content

Catalyst Calendar

Scope
Catalyst

Fri, Jul 17, 2026

1 updates
INCY
1:10 PM

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA33890 1, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as

Presentation / Abstract • Phase 1ESMO oral presentation Fri, Oct 23, 2026, 4:15 PM CETincyte.com

Mon, Jul 13, 2026

1 updates
INCY
4:00 AM

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over

Presentation / Abstract • Phase 1/2ISTH oral presentation Mon, Jul 13, 2026, EDTincyte.com

Sun, Jun 14, 2026

1 updates
INCY
4:35 PM

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib

Trial Results • Phase 2ENDO 2026 presentation Sun, Jun 14, 2026, 4:35 PM EDTincyte.com

Sat, Jun 13, 2026

2 updates
INCY
11:15 AM

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinib In essential thrombocythemia (ET), 87% of patients achieved a

Presentation / Abstract • Phase 1EHA 2026 oral presentation Sat, Jun 13, 2026, 11:15 AM EDTincyte.com
INCY
6:00 AM

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

- frontMIND study evaluating tafasitamab (Monjuvi ® /Minjuvi ®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and

Presentation / Abstract • Phase 3Plenary Abstract Session Sat, Jun 13, 2026, 6:00 AM ETincyte.com

Thu, Jun 4, 2026

1 updates
INCY
8:05 AM

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) FOSTER CITY, Calif. & WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 4, 2026-- Mirum Pharmaceuticals, Inc.

Presentation / Abstract • Phase 2Late-breaking rapid-fire presentation Sun, Jun 14, 2026, 3:30 PM CTincyte.com

Sat, May 30, 2026

1 updates
INCY
8:00 AM

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

Trial Results • Phase 3ASCO oral presentation Sat, May 30, 2026, 4:00 PM ETincyte.com